CLNN: Clene Nanomedicine Price to Earnings Adjusted for Growth Rate
Clene Inc. aims for the global implementation of nanotherapy to combat multiple sclerosis and ALS. The company's innovative drugs accelerate neuronal energy metabolism, creating a unique method of brain protection. Drug synthesis is carried out in sterile facilities in perfect technical condition. The P/E growth potential metric on GURU.Markets reflects the valuation dynamics, where the value is held at 0.00.
Analytical breakdowns for Clene Inc. (CLNN)
- current price and projected stock value:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
- net income and valuation multiples indicators:
CLNN - Net Profit|Future Profit Clene Inc.|CLNN - Price to Earnings Ratio|Future Price to Earnings clene.com|CLNN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Clene Nanomedicine|CLNN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Clene|CLNN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months clene.com|CLNN - Earnings growth in current year|Expected net earnings per share growth next year Clene Inc.
Fundamental company analysis:Clene Inc (CLNN)
Clene Inc. specializes in creating innovative nanocatalysts, leveraging a stable staff of highly qualified physicists and chemists. Analyzing the upward trend of the P/E growth ratio allows for an assessment of the effectiveness of this scientific foundation. This metric compares the current earnings multiple with the growth rate, identifying discrepancies in market value relative to development speed. A value below one signals that the asset is undervalued. Fundamental analysis of this ratio enables the determination of the fair share price for the biotech company.
Competing companies
Price/Earnings to Growth Ratio BIIB (Biogen Inc)|PEG Multiple NBIX (Neurocrine Biosciences Inc)|Regencell Corp (RGC) - Price to Earnings Adjusted for Growth Rate|AXSM - Price/Earnings to Growth Ratio|ACAD (acadia-pharm.com) - Growth-Adjusted P/E Ratio|XENE: PEG Multiple|Price to Earnings Adjusted for Growth Rate Viking Therapeutics Inc (VKTX)|Price/Earnings to Growth Multiple SUPN|CPRX: Growth-Adjusted Payback Ratio|PEG Multiple DNLI|Growth-Adjusted Market Cap to Net Income harmonybiosciences.com|Price/Earnings to Growth Ratio Biohaven BHVN|AMLX: Growth-Adjusted P/E Ratio|Trevi Pharma - PEG Multiple|Praxis Corp (PRAX) - Price/Earnings to Growth Multiple|AVXL (Anavex Life Sciences) - Price/Earnings to Growth Multiple|CBLL - Growth-Adjusted Market Cap to Net Income|PRTA (Prothena Corporation plc) - PEG Multiple|Price/Earnings to Growth Multiple Alector Therapeutics (ALEC)|Price/Earnings to Growth Ratio Annexon Inc. (ANNX)|Price/Earnings to Growth Ratio OMER (omeros.com)|Price/Earnings to Growth Ratio Neurogene Inc. NGNE|ACIU: Growth-Adjusted P/E Ratio|VYGR - Price/Earnings to Growth Ratio|NMRA (Neumora) - Growth-Adjusted P/E Ratio|Scilex Holding Co. (SCLX) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio TVGN|ACOG (Alpha Cognition Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate cogrx.com CGTX|Price/Earnings to Growth Multiple IKT (Inhibikase Therapeutics, Inc.)|PEG Multiple Cassava Sciences Inc (SAVA)|Price/Earnings to Growth Ratio Assertio ASRT|Growth-Adjusted Payback Ratio COYA|VTGN - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Ovid Therapeutics Inc.|ABOS: PEG Multiple|Price/Earnings to Growth Multiple CervoMed, Inc.|Price/Earnings to Growth Ratio Alterity Therapeutics Ltd.|Price/Earnings to Growth Ratio PEPG|PEG Multiple JUNS|RLMD - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Annovis Bio ANVS|GRCE: Growth-Adjusted P/E Ratio|Firefly Neuroscience Inc - PEG Multiple|Price to Earnings Adjusted for Growth Rate Klotho Neurosciences Inc|NRSN (neurosense-tx.com) - Price/Earnings to Growth Multiple|revivapharma.com - Growth-Adjusted Payback Ratio|MTVA (MetaVia Inc.) - PEG Multiple|NeurAxis Inc. (NRXS) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Helius Medical (HSDT)|passagebio.com - Growth-Adjusted P/E Ratio|PEG Multiple NEUP (Neuphoria Therapeutics)|NERV - Price/Earnings to Growth Multiple|ATHA: Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income Addex Therapeutics Ltd. ADXN|ALZN: PEG Multiple|Price/Earnings to Growth Multiple Cyclerion Therapeutics, Inc.|Price/Earnings to Growth Ratio Protagenic Therapeutics Inc.|Price/Earnings to Growth Ratio KTTA|Price/Earnings to Growth Ratio Cortigent, Inc. (CRGT)|Avenue Therapeutics Inc. - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Brainstorm Cell Therapeutics, Inc. BCLI|CARA: Growth-Adjusted P/E Ratio|CHRO - Price/Earnings to Growth Ratio|ELYM (Eliem Therapeutics) - Growth-Adjusted P/E Ratio|ITCI: PEG Multiple|Price to Earnings Adjusted for Growth Rate Longboard Pharmaceuticals Inc (LBPH)|Price/Earnings to Growth Multiple MRNS|PEG Multiple NKGen Biotech Corp|Price/Earnings to Growth Ratio NeuroBo Pharmaceuticals (NRBO)|SAGE (sagerx.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Synaptogenix SNPX|Trevena Inc. (TRVN) - Price to Earnings Adjusted for Growth Rate|Vigil Neuro - PEG Multiple|Anew Medical Inc. (WENA) - Price/Earnings to Growth Multiple|Cerevel Therapeutics (CERE) - Price/Earnings to Growth Ratio
